Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Several possible studies

Story checked

Weight loss alone does not explain lower heart disease risk for those on semaglutide (opens in a new tab)

medicalxpress.com · 2026-09-23

Short answerEvidenceSource

Short answer

Several possible studies

No clear answer.

More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Several studies could be the source of this story.

More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.

Open claim evidence
3

Search result

Several studies could fit.

More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.

Source paper

Source layer

The paper behind the story

The source record for this check.

The research anchor for the report.

  • Points somewhere elsepresented as the new finding

    Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial

    Publisher (opens in a new tab)
Related research

Research nearby

The papers it could be

Nearby papers when the source is unclear.

and 13 more considered

Then inspect each claim

Evidence layer

Claim by claim

What the story asserts. With no source study, there is nothing to check these against.

Claim 1 of 4Not checkedA new study published in the European Heart Journal suggests semaglutide's reduction in heart disease risk cannot be entirely explained by patients losing weight on the drug.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 2 of 4Not checkedResearchers found that in people taking semaglutide in the SELECT trial, the lower risk of serious cardiovascular disease was only partly explained by changes in known risk factors such as body weight and waist circumference.View evidenceHide evidence

As statedonly half of the reduction

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 3 of 4Not checkedThe article says semaglutide may also reduce heart disease through other mechanisms, with the authors proposing possibilities such as anti-inflammatory effects or direct effects on heart muscle or blood vessels.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 4 of 4Not checkedThe study is described as a mediation analysis based on SELECT, a randomized placebo-controlled trial of 17,604 patients with overweight or obesity, half assigned semaglutide and half placebo.View evidenceHide evidence

As stated17,604 patients; 20% lower rates of heart disease

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Finally, the search trail

Method layer

No single source study was found.

NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.

Nearby research

No exact source, but these papers are close.

PubMed, Europe PMC, Crossref · 15 candidate papers

And 10 more candidates considered.